AMMAN, Jordan, July 31, 2017 /PRNewswire/ --
Tabuk Pharmaceutical Manufacturing Company ("Tabuk"), one of the leading
Under this agreement, Dong A will grant Tabuk exclusive rights to carry out the manufacturing processes under license, commercialize and distribute Zydena in the Kingdom of Saudi Arabia & the Gulf area.
This project demonstrates Tabuk's continued commitment to patients and to offering new medicines within an ongoing collaboration with global partners to deliver on its mission to help improve the lives of patients.
"I am very pleased by this partnership and the future business we will build together, we look forward to continuing to expand our portfolio and better serving patients' needs," commented Dr. Rana Azzam, Tabuk's Senior VP of Business Development.
Dong-A's senior VP of Global business HQ, Mr. Chae. J. Lee, also commented, "We are very excited to establish this collaboration with Tabuk, a highly respected pharmaceutical company in the region, for Zydena, Dong-A's innovative PDE-5 inhibitor for patients suffering from erectile dysfunction(ED). Through our close collaboration, we look forward to making a positive impact on ED patients' quality of life in the region."
SOURCE Tabuk Pharmaceuticals
Subscribe to our Free Newsletters!
Sarcoma, is a cancer that may arise from several soft-tissues or bone. Treatment in early stages is ...
A wonder drug, soda bicarb or baking soda can be used for skin, teeth, hair, kidneys and much more ...
Melasma, also called as chloasma, is a skin hyperpigmentation problem characterized by brown spots ...View All